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Abstract 
Purpose: To examine the incidence and characteristics of metachronous contralateral breast 
cancer (CBC) among women in the Canton of Zurich, Switzerland. 
Methods: For 1980-2006, patients with unilateral invasive breast cancer (UBC) were 
analysed for metachronous CBC. Poisson regression was used to estimate incidence rates 
of metachronous CBC according to age, year of diagnosis, follow-up period since first breast 
cancer and morphology. 
Results: Of 16,323 patients with UBC, 700 (4.3%) developed a second malignant tumour of 
the opposite breast. Median age at first breast cancer was lower in the CBC group than in 
the full cohort. Median interval time between first and second breast cancer was 5.5 
(interquartile range, 2.6-10.1) years. Incidence rate at age 20-29 was 1,006 (95% confidence 
interval, CI, (452-2238) cases per 100,000 person-years and decreased to 299 (199-450) at 
80-84. Age-adjusted incidence rates according to period of diagnosis decreased from 618 
(530-721) for 1980-1984 to 329 (217-500) cases per 100,000 person-years for 2005-2006. 
Incidence rate ratio of CBC for lobular carcinoma was 1.28 (95% CI 0.99 - 1.67) adjusted by 
age group and period of diagnosis compared to ductal carcinoma. 
Conclusions: In our study, incidence rates for CBC are comparable with findings from the 
literature. A reduction in the incidence of metachronous CBC, thought to be due to adjuvant 
therapies, is seen in our data. In our cohort, younger age and lobular carcinoma was 
associated with increased risk for CBC. 
 
Keywords Metachronous contralateral breast cancer, lobular carcinoma, incidence rates, 
year of diagnosis, follow-up period  
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Introduction 
In Switzerland, about 5250 women develop a new malignant tumour of the breast 
every year. Five years after diagnosis 80% of these women are still alive (Bouchardy et al. 
2011b). Breast cancer is the most frequent malignancy in the age group 30 years and older 
and accounts for 33% of new cancer cases in the female population (Krebsregister der 
Kantone Zürich und Zug 2014). 19% of all women who die of cancer die of a malignancy of 
the breast (Bouchardy et al. 2011b). Thus, breast cancer deaths are responsible for the 
largest number of female cancer deaths in Switzerland, but, on the whole, the survival is 
favourable (Bouchardy et al. 2011b). In the Canton of Zurich breast cancer incidence 
increased up to around 2003 and then dropped slightly in the following years (Ceschi et al. 
2009). 
 A study of the Swiss National Institute for Cancer Epidemiology and Registration 
(NICER) showed an increasing prevalence of long term cancer survivors, which was also 
clearly evident in breast cancer (Lorez et al. 2013). This development is due to a better 
prognosis as a result of earlier detection and adjuvant therapies. As a consequence regular 
follow-up of these patients to detect recurrence and metachronous CBC is becoming 
increasingly important. 
A new malignant tumour of the opposite breast is the most frequent second 
malignancy of breast cancer patients (Curtis et al. 2006). The risk of a new occurrence of 
breast cancer is significantly increased compared to the general risk of developing breast 
cancer (Bernstein et al. 2003; Kollias et al. 1999; Lizarraga et al. 2013; Rubino et al. 2010; 
Sandberg et al. 2012a). The annual risk of developing a second invasive tumour of the 
opposite breast has been reported to be between 0.3-0.8% (Kollias et al. 1999; Lizarraga et 
al. 2013; Narod 2014; Nichols et al. 2011). This means a woman with breast cancer has 
approximately a doubled risk of developing a second primary tumour of the breast compared 
to the risk of breast cancer in the general female population (Sandberg et al. 2012a). 
A reduction in the global incidence of CBC over the last couple of decades is thought 
to be due to adjuvant chemotherapeutic therapies. Tamoxifen, an antagonist of oestrogen 
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receptors in breast tissue, is used in the endocrine treatment of hormone-sensitive breast 
cancer. It has been regularly prescribed to breast cancer patients since the 1980s (Jordan 
2003). Its benefit has been shown in many - also recent - studies (Bouchardy et al. 2011a; 
Chen et al. 1999; Cuzick and Baum 1985; Narod 2014; Sandberg et al. 2012a; Yerushalmi et 
al. 2009), which has finally led to a wide clinical acceptance (Jordan 2003). Tamoxifen was 
approved in Switzerland in 1976. 
Switzerland is one of the European countries with the highest incidence rates of 
breast cancer (Bouchardy et al. 2011b). The number of women with a diagnosis of breast 
cancer living in Switzerland is continually rising. With an increasing survival, the demand for 
good treatment and care for cancer patients is growing. The aim of our study is to examine 
the incidence of CBC and the histology of the index cancer in the Canton of Zurich between 
1980 and 2011, particularly as breast cancer represents a major health care issue in 
Switzerland. 
 
Materials and Methods 
The epidemiological Cancer Registry Zurich and Zug is the largest cancer registry in 
Switzerland. The cancer registry in the Canton of Zurich was one of the first cancer registries 
to be founded in Switzerland in a close collaboration of the Institute of Pathology of the 
University Hospital Zurich and the Institute of Social and Preventive Medicine of the 
University of Zurich. The Cancer Registry Zurich exists since 1980. In the study period, the 
population of the Canton of Zurich increased to well over a million (BFS Statistical office 
2010).  
Inclusion criteria. In our present study, we included all female patients with UBC 
recorded in the population-based Cancer Registry Zurich and Zug from the beginning of the 
aggregation of data in 1980 up until the year 2006, therefore allowing for a minimum follow-
up period of five years for every notified cancer case for detecting patients who developed 
metachronous CBC up until 2011. Of 19,271 breast cancer patients identified in our 
database, we excluded all patients with other malignancies prior to the first incidence of 
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breast cancer, in situ breast cancer, morphologies breast sarcoma and lymphoma and 
unclassified malignant breast tumours (n=615). Patients with malignant tumours before CBC 
were censored at date of other malignancy. As in some other studies older patients - older 
than 84 years of age in our case - were not included because of the insufficient follow-up of 
older patients (Font-Gonzalez et al. 2013; Kollias et al. 1999; Nichols et al. 2011). Patients 
younger than 20 were also excluded because of the small number of cases (n=1175). We 
also excluded patients with a follow-up of less than three months to distinguish between 
synchronous and metachronous cancer, an interval time often used by other groups (n=878) 
(Alkner et al. 2011; Sandberg et al. 2012a; Sandberg et al. 2012b; Schmid et al. 2011). 
Patients with a follow-up of less than 90 days had usually died within three months of initial 
diagnosis. Further, we excluded 280 patients with non-valid data, predominantly due to a 
lack of information on the laterality of tumours.  
Statistical analyses. The person-time at risk for calculation of incidence of CBC 
started three months after initial primary breast cancer until occurrence of CBC or the 
endpoints of exclusion criteria, i.e., second non-breast cancer, death or end of study period 
(December 31, 2011). Because of insufficient follow-up in most cases person-years were 
simulated with Swiss breast cancer survival data provided by NICER. A constant hazard rate 
of 0.0575 y-1 for survival after UBC was assumed for the whole period from 1980-2011 to 
compute random survival time. Univariate and multivariate Poisson regression was 
performed to estimate incidence rates and incidence rate ratios of metachronous CBC 
adjusting for age at diagnosis and year of diagnosis of UBC, morphology of UBC and follow-
up period. To consider overdispersion we used quasi-Poisson regression. Results were 
presented as number of cases per 100,000 person-years and 95 % confidence intervals 
(95% CI) were obtained. Statistical analyses were performed in R (version 2.13.1, The R 
Foundation for Statistical Computing, Vienna, Austria).  
 
Results 
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In the study period from 1980 to 2006, of 19,271 female breast cancer patients living 
in the Canton of Zurich at the time of diagnosis 16,323 women with unilateral invasive breast 
cancer met the eligibility requirements. Of this cohort of UBC 700 (4.3%) developed a second 
malignancy of the opposite breast (table 1). Highest incidence rates of CBC were noted in 
patients with diagnosis of first breast cancer at a younger age (table 2). Median age at first 
breast cancer was 55 (interquartile range [IQR] 46-64) in the CBC group compared to 60 
(IQR 50-70) years in the full cohort. The median interval time to CBC was 5.5 (IQR 2.6-10.1) 
years. The median estimated follow-up time was 7.8 (IQR 4.2-12.8) years (table 1). Crude 
incidence rates of CBC decreased by period of diagnosis and by age at index cancer (table 
2). Incidence rates remained stable throughout the follow-up period (table 2), but CIs became 
wider with follow-up period. There was no relevant difference between crude and age-
adjusted incidence rates by period of diagnosis (figure 1). The estimated annual incidence 
rates varied between 463 per 100,000 person-years (95% CI 410-522) for the follow-up 
period 0-3 years and 513 (95% CI 407-646) for the follow-up period 12-15 years (figure 2). 
There was no relevant difference between crude and age-adjusted incidence rates (data not 
shown). 
Lobular carcinoma had higher crude and age-adjusted incidence rates than ductal 
carcinoma but the confidence intervals overlapped. Age-adjusted rates did not differ 
materially (data not shown). Incidence rate ratio of CBC from univariate Poisson regression 
for lobular morphology compared to patients with ductal morphology had no significant effect 
(1.15, 95% CI  0.83 - 1.59), whereas adjusted by age group and period of diagnosis 
incidence rate ratio was 1.28 (95% CI  0.99 - 1.67) (table 3). 
Sensitivity analysis. To study how the lag time between breast cancer at index and 
CBC affected incidence rate ratios, multivariate Poisson regression was performed  for lag 
times of 3, 6 and 12 months. Incidence rates and incidence rate ratios did not change or 
showed only slight alterations whereas the power decreased due to lost cases which fell into 
the lag time (results not shown). 
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Discussion 
Declining incidence rates of CBC over the last couple of decades have been reported 
in many countries. Numerous studies support this finding (Bernstein et al. 2003; Bouchardy 
et al. 2011a; Hartman et al. 2007; Lizarraga et al. 2013; Nichols et al. 2011; Sandberg et al. 
2012a; Vichapat et al. 2011b). As the Cancer Registry has been collecting population-based 
data over a long period of time we were able to show a distinct decrease in CBC incidence 
since around 1985 in the Canton of Zurich. 
Adjuvant therapies are said to be responsible for the reduction in the incidence of 
metachronous CBC. Tamoxifen reduces the risk of CBC by approximately 40% (Bertelsen et 
al. 2008; Rutqvist et al. 1991). About 70% of all breast cancers are oestrogen receptor 
positive. So far, the use of tamoxifen/aromatase inhibitor had been recommended for 5 
years. But several recent studies demonstrated a benefit of prolonged use of tamoxifen, 
preventing recurrence and CBC and also improving survival. On this account new guidelines 
have been issued by the American Society of Clinical Oncology (ASCO) (Burstein et al. 
2014). Trials initiated by the International Breast Cancer Study Group (IBCSG) exhibited a 
favourable result of aromatase inhibitor and ovarian suppression for premenopausal women 
with receptor positive breast cancer, a group which had so far been given tamoxifen (Pagani 
et al. 2014). Correspondingly, a survey with data from the National Cancer Institute's 
Surveillance, Epidemiology, and End Results (SEER) database in the U.S. showed that 
women with hormone receptor negative tumours had a substantially higher risk of developing 
CBC than woman with receptor positive breast cancer (Kurian et al. 2009). The focus of most 
studies concerning outcome is on regional or distant recurrence, but the incidence of CBC is 
also always reduced as an effect of adjuvant therapies. 
In our study population, younger age at incidence of the initial breast cancer was a 
risk factor for CBC as also found in various other studies (Bernstein et al. 2003; Chen et al. 
1999; Hartman et al. 2007; Kollias et al. 1999; Kurian et al. 2009; Lizarraga et al. 2013; 
Narod 2014; Nichols et al. 2011; Rubino et al. 2010; Sandberg et al. 2012b; Schaapveld et 
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al. 2008; Verkooijen et al. 2007; Vichapat et al. 2011a). In the Canton of Vaud, the age 
incidence pattern of CBC was examined as it was not comparable to the pattern of incidence 
for most cancers or breast cancer. A peak was reached at age 30-39 and the incidence 
gradually declined afterwards up to 70 years of age, reaching levels similar to primary breast 
cancers in that age group (Levi et al. 2001). In a publication of the Geneva Cancer Registry, 
young age was associated with an increased risk for CBC in women with ER-negative 
tumours, but the study found family history in these patients an even stronger predictor for 
contralateral disease (Bouchardy et al. 2011a). A deficiency of our study is missing 
information on hormone status of breast cancer and, thus, we cannot replicate the finding of 
the Geneva Cancer Registry. Furthermore, a slight increase in the incidence of breast cancer 
in younger Swiss women has recently been reported (Bodmer et al. 2015). Young women 
might still have an increasing risk of developing a malignant tumour of the breast compared 
to a declining incidence in general and are probably more likely to develop CBC. A recently 
published paper with data from the Danish Cancer Registry examined the influence of the 
longer follow-up of younger patients on the incidence of CBC and also still found a 
decreasing incidence of CBC with age when limiting the follow-up time (Rasmussen et al. 
2014). 
Lobular cancer is frequently seen as a risk factor for CBC (Arpino et al. 2004; 
Bernstein et al. 2003; Chen et al. 1999; Kollias et al. 1999; Lizarraga et al. 2013; Narod 
2014; Schaapveld et al. 2008; Soran et al. 2014), but not all studies show this result 
(Lizarraga et al. 2013; Narod 2014; Rubino et al. 2010; Verkooijen et al. 2007; Vichapat et al. 
2011b). Invasive lobular carcinoma represents about 10-15% of breast cancers. It tends to 
occur at a somewhat older age than invasive ductal/no special type carcinoma. The Geneva 
Cancer Registry reported a higher risk of synchronous bilateral breast cancers in patients 
with lobular histology, but not of metachronous tumours (Verkooijen et al. 2007). In other 
studies lobular carcinoma corresponded to a higher rate of CBC (Arpino et al. 2004; 
Bernstein et al. 2003; Chen et al. 1999; Kollias et al. 1999; Lizarraga et al. 2013; Narod 
2014; Schaapveld et al. 2008; Soran et al. 2014). Our data supports this finding. The 
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adjusted incidence rates showed a higher risk for CBC after lobular compared to ductal 
carcinoma (table 3). A study of the risk of invasive cancer after lobular carcinoma in situ 
found an equal risk of malignancies in both breasts and a higher incidence of invasive lobular 
carcinoma than would be expected (Chuba et al. 2005). A recent analysis of genetic 
predisposition to in situ and invasive lobular carcinoma of the breast found a novel lobular-
specific breast cancer gene locus (Sawyer et al. 2014). All this might support the assumption 
of invasive lobular carcinoma as a general risk factor for CBC. 
The incidence rate of CBC was in the range of 300-1,000 per 100,000 person-years. 
This is consistent with other studies(Kollias et al. 1999; Rubino et al. 2010). The risk of 
second breast cancer remained higher during the whole follow-up period compared to the 
general risk of breast cancer in the female population. The risk of a first primary tumour of 
the breast in the canton of Zurich in 2002-2006 was 110.8 per 100,000 person-years and 
therefore the risk of CBC about three times higher than the risk of a woman to develop breast 
cancer in the same period. 
Our data showed constant incidence rates of CBC during the follow-up after primary 
breast cancer. The Danish study referred to above exhibited an increasing incidence in 
younger patients with a peak 2-4 years after diagnosis, but when adjusted for age and 
calendar period, incidence rates where more or less constant over time (Rasmussen et al. 
2014). We are not able to investigate the influence of age on the time to incidence of CBC, 
as our number of cases is too small for examining incidence rates for certain age groups with 
regard to follow-up. Further studies about the influence of the follow-up period on the 
incidence of CBC are necessary. 
To separate synchronous from metachronous contralateral breast cancer cases we 
used an interval time between the first and the second breast cancer of three months. 
Contralateral tumours occurring within three months were classified as synchronous. The 
WHO Classification of Tumours of the Breast adopts this definition, which is used frequently 
in studies (Alkner et al. 2011; Hartman et al. 2007; Sandberg et al. 2012b; Schmid et al. 
2011), but also mentions the benefit of a longer time interval for epidemiological 
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assessments. Many studies favour a longer cut-off time to distinguish bilateral breast cancers 
(Bernstein et al. 2003; Londero et al. 2014; Nichols et al. 2011; Rubino et al. 2010; 
Schaapveld et al. 2008; Verkooijen et al. 2007; Vichapat et al. 2011a; Vichapat et al. 2012; 
Vichapat et al. 2011b; Yerushalmi et al. 2009). As there is no consensus concerning these 
definitions, we conducted further analyses with different cut-off times. Our comparison of cut-
off times of three, six and twelve months did not show any significant differences, and we 
therefore concentrated on the one time interval of three months for our final calculations. 
A shortcoming of our study is the lack of information on tumour stage. Information on 
distant spread at diagnosis would allow for better comparison with other studies, as stage IV 
index tumours are generally excluded. Whether CBC should be looked at as distant spread 
or new primary is still open to debate (Rubino et al. 2010; Vichapat et al. 2012; Yerushalmi et 
al. 2009). Complete data on tumour characteristics and therapies is not available for our 
present study. In comparison, in 2007 the Registry of the Canton of Zurich participated in an 
extensive survey on the patterns of care in breast cancer patients in Switzerland. The Cancer 
Registry of the Canton of Zurich collected information on roughly 500 breast cancer patients 
diagnosed from 2003-2005. 4% of the cases in the Canton of Zurich were diagnosed at stage 
IV. Oestrogen receptor expression was found in 79% of the patients in the Canton of Zurich, 
and in 97% of patients with hormone-responsive disease, endocrine therapy had been 
prescribed (Ess et al. 2010). Therefore, it can be stated that at the beginning of the year 
2000 female breast cancer patients in the Canton of Zurich with hormone-sensitive tumours 
were basically all receiving chemoprophylaxis. 
The high quality of the Registry's cancer data concerning incidence and morphology 
of cancer cases of all the inhabitants of the Canton of Zurich and the completeness of 
registration are a good basis for future endeavours in epidemiological studies (Krebsregister 
der Kantone Zürich und Zug 2014). 
 
Conclusions 
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Declining incidence rates of CBC since 1985 in the Canton of Zurich confirm trends observed 
in other studies. The risk of CBC and recurrence after UBC still calls for a continuing follow-
up after breast cancer, despite this positive development. 
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Table1: Characteristics of breast cancer cohort, Canton of Zurich 1980-
2006.  
Cohort  CBC 
BC1  BC2 
N  16,323  700  700 
Age (years) 
mean (SD)  60 (13)  56 (13)  63 (13) 
median (IQR)  60 (50‐70)  55 (46‐64)  63 (53‐73) 
Follow up time (years) 
mean (SD)  9.2 (6.6) 
median (IQR)  7.8 (4.2‐12.8) 
Interval time to CBC (years) 
mean (SD)  6.9 (5.7) 
median (IQR)  5.5 (2.6‐10.1) 
 
CBC, contralateral breast cancer; BC1, index case (first breast cancer); BC2, second primary 
breast cancer; SD, standard deviation; IQR, interquartile range 
 
  
[13] 
 
Table 2: Incidence rates of CBC (cases per 100,000 person-years), Canton of Zurich 
1980-2006. 
Total N  Cases N  Percentage Person years Incidence 95% CI 
All  16323  700  4.3% 150289 466 (433‐502) 
Diagnosis period 
1980 ‐ 1984  2498  162  6.5% 26197 618 (530‐721) 
1985 ‐ 1989  2729  169  6.2% 29737 568 (489‐661) 
1990 ‐ 1994  2809  129  4.6% 29865 432 (363‐513) 
1995 ‐ 1999  3293  127  3.9% 30378 418 (351‐497) 
2000 ‐ 2004  3720  91  2.4% 27430 332 (270‐407) 
2005 ‐ 2009  1274  22  1.7% 6682 329 (217‐500) 
Age 
20 ‐ 29  79  6  7.6% 597 1006 (452‐2238) 
30 ‐ 39  870  52  6.0% 8359 622 (474‐816) 
40 ‐ 49  3010  193  6.4% 31526 612 (532‐705) 
50 ‐ 59  3908  186  4.8% 38442 484 (419‐559) 
60 ‐ 69  4018  152  3.8% 37160 409 (349‐480) 
70 ‐ 79  3258  88  2.7% 26506 332 (269‐409) 
80 ‐ 84  1180  23  1.9% 7699 299 (199‐450) 
Histology 
ductal  11380  474  4.2% 104542 453 (414‐496) 
lobular  1683  77  4.6% 14796 520 (416‐651) 
others  3260  149  4.6% 30950 481 (410‐565) 
Follow‐up period 
0 ‐ 3  16323  266  1.6% 57481 463 (410‐522) 
4 ‐ 7  12430  191  1.5% 41137 464 (403‐535) 
8 ‐ 11  7920  121  1.5% 24408 496 (415‐592) 
12 ‐ 15  4568  72  1.6% 14042 513 (407‐646) 
16 ‐ 19  2594  23  0.9% 7562 304 (202‐458) 
20 ‐ 23  1339  20  1.5% 3797 527 (340‐817) 
24 ‐ 27  584  5  0.9% 1522 329 (137‐789) 
28 ‐ 31  208  2  1.0% 341 587 (147‐2346) 
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Table 3: Incidence rate ratio computed from a univariate and a multivariate Poisson regression, 
Canton of Zurich 1980-2006 
Univariate  Multivariate 
Rate ratio  95% CI  P‐value  Rate ratio 95% CI  P‐value 
Diagnosis period 
1980 ‐ 1984  1.00  (reference)  1.00 (reference) 
1985 ‐ 1989  0.92  (0.70 ‐ 1.21)  0.55  0.86 (0.68 ‐ 1.11)  0.25 
1990 ‐ 1994  0.70  (0.52 ‐ 0.94)  0.02  0.66 (0.51 ‐ 0.86)  0.003 
1995 ‐ 1999  0.68  (0.50 ‐ 0.91)  0.01  0.63 (0.49 ‐ 0.83)  0.001 
2000 ‐ 2004  0.54  (0.39 ‐ 0.75)  0.000  0.50 (0.38 ‐ 0.67)  0.00001
2005 ‐ 2009  0.53  (0.30 ‐ 0.95)  0.03  0.51 (0.31 ‐ 0.82)  0.01 
Age 
20 ‐ 29  2.46  (0.93 ‐ 6.53)  0.07  2.58 (1.07 ‐ 6.20)  0.04 
30 ‐ 39  1.52  (1.04 ‐ 2.22)  0.03  1.45 (1.03 ‐ 2.04)  0.03 
40 ‐ 49  1.50  (1.16 ‐ 1.93)  0.002  1.45 (1.16 ‐ 1.83)  0.002 
40 ‐ 49  1.50  (1.16 ‐ 1.93)  0.002  1.45 (1.16 ‐ 1.83)  0.002 
50 ‐ 59  1.18  (0.92 ‐ 1.53)  0.20  1.17 (0.93 ‐ 1.48)  0.18 
60 ‐ 69  1.00  (reference)  1.00 (reference) 
70 ‐ 79  0.81  (0.59 ‐ 1.11)  0.20  0.79 (0.59 ‐ 1.04)  0.10 
80 ‐ 89  0.73  (0.43 ‐ 1.23)  0.24  0.71 (0.45 ‐ 1.15)  0.17 
Histology 
ductal  1.00  (reference)  1.00 (reference) 
lobular  1.15  (0.83 ‐ 1.59)  0.41  1.28 (0.99 ‐ 1.67)  0.06 
others  1.06  (0.83 ‐ 1.36)  0.64  0.92 (0.74 ‐ 1.14)  0.45 
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